scorecardresearch
Monday, September 22, 2025
TopicPembrolizumab

Topic: pembrolizumab

This experimental lung cancer drug outperforms blockbuster medicine Keytruda. But there’s a catch

In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.

On Camera

Skin cancer is no more an ‘old person’s disease’

The sun isn’t acting alone—it has an accomplice in pollution. Environmental toxins weaken our skin’s natural barrier.

Market regulator SEBI clears Adani Group of impropriety alleged by Hindenburg Research

SEBI probe concluded that purported loans and fund transfers were paid back in full and did not amount to deceptive market practices or unreported related party transactions.

60 yrs on, veterans recall lessons from 1965 India-Pakistan war. ‘Equipment alone doesn’t win battles’

A common thread runs through the memories of soldiers of the 1965 war—ingenuity, courage and camaraderie that withstood an apparently technologically superior foe.

India doesn’t give walkovers to Pakistan in war. Here’s why it shouldn’t do it in cricket either

Many really smart people now share the position that playing cricket with Pakistan is politically, strategically and morally wrong. It is just a poor appreciation of competitive sport.